



International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.4, No.4, pp 1834-1839, Oct-Dec 2012

# Exploring Structural Requirements For PPARx Modulation Of Benzoyl 2-Methyl Indoles Using Physico-Chemical Parameters

# Love Kumar Soni\*

Molecular Modelling Study Group, Drug Design and Discovery Research School of Pharmacy, Devi Ahilya University, Takshashila Campus, Ring Road, Indore -452017, India

## \*Corres.author: lovesoni@hotmail.com

**Abstract:** Peroxisome proliferator-activated receptor *gamma* (PPAR $\gamma$ ) has been the focus of intense research, as ligands for this receptor have emerged as potent insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM). A series of benzoyl 2-methyl indoles was subjected to quantitative structureactivity relationship (QSAR) analysis. The studies showed that the electronic properties, energy of lowest unoccupied molecular orbital ( $E_{LUMO}$ ) and dipole moment (DPL), and principal moment of inertia-Z component (PMI-Z) of the molecule can be explored to design potent PPAR $\gamma$  modulators. LUMO, which is indicative of -bonding interaction of species crucial for the electrophilicity of the molecules, suggested that molecules are able to interact with electron-rich area at the receptor site. DPL is related to the molecular charge distribution in Z-component and can be altered through the incorporation of electronegative group. The QSAR study provides important structural insights in designing of potent PPAR $\gamma$  modulators. **Keywords:** peroxisome proliferator-activated receptor (PPAR), type 2 diabetes mellitus (T2DM), quantitative structure activity relationship analysis (QSAR), indoles, selective PPAR $\gamma$  modulators.

### **Introduction**

The peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) has been the focus of intense research during the past decade because ligands for this receptor have emerged as potent insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM). Increased levels of circulating free fatty acids and lipid accumulation in nonadipose tissue have been implicated in the development of insulin resistance. This situation is improved by PPARy ligands, which improve the insulin sensitivity.<sup>1</sup> Between 1997 and 1999, a new class of drugs called 'glitazones'<sup>2</sup> was approved by the FDA for the treatment of type 2 diabetes. These agents are PPARy modulators, share a common partial chemical structure: thiazolidine-2,4-diones (TZD).

Glitazones correct hyperglycemia by enhancing tissues' sensitivity to insulin. Because

of this mechanism of action, glitazone treatment is not associated with dangerous hypoglycemic incidents that have been observed with conventional sulfonylurea agents and insulin therapy. Glitazones, while efficacious, exhibit significant liabilities; they are associated with edema and weight gain in man. In addition, cardiac hypertrophy is observed in preclinical rodent models. These adverse effects preclude glitazones from being used as frontline therapy in T2DM, suggesting that pursuit of a safer secondgeneration human PPARy (hPPARy) agonist is desirable.

Selective PPAR $\gamma$  modulators (SPPAR $\gamma$ Ms), which are also known as hPPAR $\gamma$  partial agonists, have recently attracted much interest. Selective modulation of the hPPAR $\gamma$  could provide significant anti-diabetic activity while concurrently reducing or eliminating PPAR $\gamma$ -mediated side-

effects.<sup>3-5</sup> We therefore initiated a search for non-TZD PPAR $\gamma$  ligands with the goal of finding novel insulin sensitizers. Owing to continuing zeal in exploring the structural insights to aid the design of safer novel insulin sensitizers<sup>6-10</sup>, our research has been tuned to cater the needs of changing scenario of anti-diabetic therapy. In this context QSAR analysis of Benzoyl 2-methyl indoles<sup>11</sup> as selective PPAR $\gamma$  modulators was performed to identify the associated molecular properties, which are responsible for drug-receptor interactions.

#### **Materials and Methods**

The in vitro activity data of PPAR $\gamma$  by benzoyl indoles (Table 1) were taken from the reported work<sup>11</sup>. The biological activity data (IC<sub>50</sub> in  $\mu$ *M*) was converted into negative logarithmic dose (pIC<sub>50</sub>) for QSAR analysis to reduce skewness of data set.

The series was subjected to molecular modeling and QSAR studies using CS Chem-Office Software version 6.0<sup>12</sup> running on a P-III processor. Energy minimization was carried out using molecular mechanics (MM2) until the root mean square (RMS) gradient value became smaller than 0.1 kcal/mol Å. Minimized molecule was subjected to re-optimization via the Hamiltonians approximations using Austin model-1 (AM1) method until the RMS gradient became smaller than 0.0001 kcal/mol Å<sup>13</sup>. The geometry optimization of the lowest energy structure was carried by Chem3D ultra version 6.0 using Eigenvector following (EF) routine. The descriptor values for all the molecules were calculated using "compute properties module" of program.

All the descriptor values for the molecules considered as independent variables and PPAR $\gamma$  binding data (pIC50) were taken as dependent variable. Sequential multiple linear regression analysis method was used to develop tri-variant relationship between pIC<sub>50</sub> and descriptors.

Calculated thermodynamic descriptors included critical temperature (T<sub>c</sub>), ideal gas thermal capacity (C<sub>p</sub>), critical pressure (P<sub>c</sub>), boiling point (BP), Henry's law constant (H), stretch bend energy ( $E_{SB}$ ), bend energy ( $E_B$ ) and log P.

Steric descriptors derived were Connolly accessible area (SAS), Connolly molecular area (CMA), Connolly solvent excluded volume (CSEV), exact mass (EM), molecular weight (MW), principal moment of inertia-X component (PMI-X), principal moment of inertia-Y component (PMI-Y) and principal moment of inertia-Z component (PMI-Z), molar refractivity (MR) and ovality (OVAL).

Electronic descriptors, such as electronic energy  $(E_{Elc})$ , highest occupied molecular orbital

energy ( $E_{HOMO}$ ), lowest unoccupied molecular orbital energy ( $E_{LUMO}$ ), X-component of dipole moment ( $DPL_X$ ), Y-component of dipole moment ( $DPL_Y$ ), Z-component of dipole moment ( $DPL_Z$ ), resultant dipole moment (DPL), repulsion energy ( $E_{NR}$ ), VDW-1,4- energy ( $E_{14}$ ), Non-1, 4-VDW energy ( $E_V$ ) and total energy (E) were calculated.

Sequential multiple linear regression analysis method was used to perform QSAR analysis employing in-house program VALSTAT<sup>14</sup>. In sequential multiple regression, the program searches for all permutations and combinations sequentially for the data set. Here, it searched for 7,770 combinations and gave multivariant equations, based on squared correlation coefficient. The  $\pm$  data within the parentheses are the standard error, associated with coefficient of the descriptors in regression equations. The best model was selected on the basis of various statistical parameters such as correlation coefficient (r), standard error of estimation (SE), sequential Fischer test (F), bootstrapping squared correlation coefficient  $(r_{bs}^{2}),$ bootstrapping standard deviation  $(S_{bs})$  cross-validated squared correlation coefficient (q<sup>2</sup>) and randomization test (chance).

#### **Results and Discussion**

All the descriptor values for the molecules were considered as independent variables and  $pIC_{50}$  was taken as dependent variable. Sequential multiple linear regression analysis method was used to develop tri-variant relationship between  $pIC_{50}$  and descriptors. When data set was subjected to sequential multiple linear regression analysis, in order to develop QSAR model, various statistically significant equations with coefficient of correlation ( $r \ge 0.92$ ) were obtained (Table 2 and 3). Equation 1 was considered as model (Table 4 and Fig. 1).

 $pIC_{50} = 0.164 + 6.746e-005*PMI-Z + 0.434*DPL + 3.709*E_{LUMO}$ n = 17, r = 0.937, r<sup>2</sup> = 0.878, SE = 0.480, F = 31.145, q<sup>2</sup> = 0.802

The model having good correlation coefficient value explains 87.8% variance in the activity. The standard error of estimation (SE = 0.480) and a higher F value rendering the model statistically significant. The data showed overall better statistical significance >99.9% with  $F_{(3,13)}$  = 31.145 against the tabulated value for sequential Fischer test at 99.9% significant ( $F_{(3,13)}$  0.001)= 11.9). The inter-correlations of the descriptor in the model were low, indicating that all the



Comp d.	$R_1$	$R_2$	$\mathbf{R}_3$	$IC_{50}(\mu M)^a$	pIC <sub>50</sub>			
1	Cl	OCH <sub>3</sub>	2-COOH	6.28	5.202			
2	Cl	OCH <sub>3</sub>	3-COOH	0.208	6.682			
3	Cl	OCH <sub>3</sub>	4-COOH	4.69	5.329			
4	Cl	OCH <sub>3</sub>	2-OCH <sub>2</sub> COOH	0.333	6.478			
5	Cl	OCH <sub>3</sub>	3-OCH <sub>2</sub> COOH	0.099	7.004			
6	Cl	OCH <sub>3</sub>	2-OCH(Me)COOH	0.084	7.076			
7	Cl	OCH <sub>3</sub>	3-OCH(Me)COOH	0.049	7.310			
8	Cl	OCH <sub>3</sub>	4-OCH(Me)COOH	2.14	5.670			
9	Cl	OCH <sub>3</sub>	2-OC(Me) <sub>2</sub> COOH	0.079	7.102			
10	Cl	OCH <sub>3</sub>	3-OC(Me) <sub>2</sub> COOH	0.045	7.347			
11	Cl	OCH <sub>3</sub>	4-OC(Me) <sub>2</sub> COOH	0.914	6.039			
12	OCH <sub>3</sub>	OCF <sub>3</sub>	2-OCH(Me)COOH	0.023	7.638			
13	OCH <sub>3</sub>	OCF <sub>3</sub>	2-OCH(Me)COOH	0.002	8.699			
14	OCH <sub>3</sub>	OCF <sub>3</sub>	2-OC(Me) <sub>2</sub> COOH	0.001	9			
15	OCH <sub>3</sub>	OCF <sub>3</sub>	3-OCH(Me)COOH	0.001	9			
16	OCH <sub>3</sub>	OCF <sub>3</sub>	3-OCH(Me)COOH	0.003	8.523			
17	OCH <sub>3</sub>	OCF <sub>3</sub>	3-OC(Me) <sub>2</sub> COOH	0.003	8.523			
<sup>a</sup> Average of two experiments. Data presented as mean + SEM								

descriptors were contributing independently to the biological activity. The contribution of descriptors to model is in the ratio PMI-*Z*: *DPL*:  $E_{LUMO}$ : 3.822: 1: 1.479 in normalized data.

The model was subjected to leave-one-out crossvalidation method, The value of cross-validated squared correlation co-efficient ( $q^2$ = 0.802), predictive residual sum of square ( $S_{PRESS}$ = 0.612) and standard error of predictivity ( $S_{DEP}$ = 0.535) suggested good predictive ability of the biological activity. The bootstrapping squared correlation coefficient ( $r^2_{bs}$ =0.886) suggested the robustness of the model and contribution of molecular descriptor values of each molecule to the correlation was nearly same. Randomized biological activity data test (chance <0.001) revealed that the result was not based on chance correlation. The QSAR Study revealed that  $E_{LUMO}$ , PMI-Z and Dipole were the principle descriptors contributed positively for the PPAR $\gamma$  modulator activity.  $E_{LUMO}$ , indicative of bonding interaction, is crucial for the electrophilicity of the molecules, suggested that molecules are able to interact with electron-rich area at the receptor site. Dipole, related to the molecular charge distribution, can be altered through the incorporation of electronegative group. Principle PMI-Z, Moments of Inertia-Z component, suggests the orientation of the aromatic ring bearing bulkier substitution along Zaxis for better activity.

The QSAR Study revealed that electronegative substitution, which enhances electrophilicity of the molecule, with orientation of the aromatic ring bearing bulkier substitution along Z-axis, could be helpful in designing the Selective PPAR $\gamma$  modulators for the management of type 2 diabetes mellitus.

Table 2—QSAR statistics of significant equations												
Eqn. no.	<b>Regression Equations</b>	$r^2$	SE	F	ICWP (Up to)	$r_{bs}^2$	$\mathbf{S}_{\mathrm{bs}}$	Chance	Outlier	$q^2$	S <sub>PRESS</sub>	$S_{DEP}$
1	pIC <sub>50</sub> =0.164+6.746e-005*PMI-Z +0.434*DPL +3.709*E <sub>LUMO</sub>	0.878	0.480	31.145	0.485	0.894	0.067	< 0.001	Nil	0.801	0.612	0.635
2	pIC <sub>50</sub> =44.331-0.088*BP+0.062*CAA -7.643e-005*PMI-X	0.877	0.483	30.639	0.845	0.906	0.044	< 0.001	Nil	0.781	0.643	0.562
3	pIC <sub>50</sub> =1.969-0.002*HF+5.899e-005* PMI-Y-0.329*SE	0.863	0.509	27.206	0.828	0.892	0.066	< 0.001	Nil	0.753	0.683	0.597
4	pIC <sub>50</sub> =3.474+3.985e-005*PMI-Y +1.175* <i>E</i> <sub>LUMO</sub> +0.114*DDE	0.861	0.512	26.773	0.786	0.902	0.061	< 0.001	Nil	0.749	0.688	0.602
5	pIC <sub>50</sub> =58.029-0.066*CT+0.039* CMA +6.583e-005*PMI-Y	0.859	0.515	26.472	0.878	0.894	0.065	< 0.001	Nil	0.734	0.708	0.619

Table 3—Inter-correlation matrix of parameters used in QSAR model								
	PMI-Z	DPL	$E_{LUMO}$					
PMI-Z	1							
DPL	0.225	1						
$E_{LUMO}$	0.156	0.486	1					

Table 4—Observed (Obs.), calculated (Cal.) and leave-one-out predicted									
(Pred.) pIC <sub>50</sub> data of									
Comme	pIC <sub>50</sub>			ZCaana	Residual				
Compa.	Obs	Cal.	Pred.	Z-Score					
1	5.202	5.764	6.075	-1.299	0.562	0.873			
2	6.682	6.219	6.067	1.071	-0.463	-0.615			
3	5.329	5.201	5.139	0.295	-0.128	-0.19			
4	6.478	6.795	6.850	-0.733	0.317	0.372			
5	7.004	6.523	6.404	1.114	-0.481	-0.6			
6	7.076	6.540	6.411	1.239	-0.536	-0.665			
7	7.310	7.479	7.527	-0.391	0.169	0.217			
8	5.670	5.807	5.911	-0.319	0.137	0.241			
9	7.102	7.100	7.100	0.005	-0.002	-0.002			
10	7.347	7.100	7.015	0.570	-0.247	-0.332			
11	6.039	6.796	7.004	-1.750	0.757	0.965			
12	7.638	8.307	8.402	-1.546	0.669	0.764			
13	8.699	8.456	8.415	0.563	-0.243	-0.284			
14	9	8.780	8.731	0.508	-0.22	-0.269			
15	9	8.328	8.207	1.555	-0.672	-0.793			
16	8.523	8.533	8.537	-0.022	0.01	0.014			
17	8.523	8.895	9.005	-0.860	0.372	0.482			

Table 4 Observed (Obs) as levelated (Cal) and leave and ant mudicted

Fig. 1—Scatter plot of observed versus calculated (Cal.) and leave-one-out predicted (Pred.) pIC<sub>50</sub> activity derived from the model



#### Acknowledgment

Author is thankful to the Head, School of Pharmacy, DAVV, Indore for providing facilities to complete this work.

#### **References**

- 1 Rangwala S M and Lazar M A, Peroxisome proliferator-activated receptor  $\gamma$  in diabetes and metabolism Trends in Pharmacological Sciences, 2004, 25 (6), 331-336.
- 2 Hulin, B.; McCarthy, P. A.; Gibbs, E. M. Curr. Pharm. Des. 1996, 2, 85.

- Cock, T.-A.; Houten, S. M.; Auwerx, J. 3 EMBO Rep. 2004, 5, 142
- 4 Miller, A. R.; Etger, G. J. Expert Opin. Investig. Drugs 2003, 12, 1489.
- Gurnell, M.; Savage, D. B.; Chatterjee, V. K. 5 K.; O\_Rahilly, S. J. Clin. Endocrinol. Metab. 2003, 88, 2412.
- 6 Soni L.K., Gupta A.K. and Kaskhedikar S.G., 3D-QSAR Analysis of Novel Tricyclic-αalkyloxyphenylpropionic Acids as PPAR-y Agonists, Indian Drugs, 2004, 41 (12), 714-721.

- 7 Hemalatha R., Soni L.K., Gupta A.K. and Kaskhedikar S.G., QSAR Analysis of 5substituted-2-Benzoylaminobenzoic acids as PPAR Modulator, *E-J. Chem*, 2004, 01 (05), 243-250.
- 8 Soni L.K., Gupta A.K, and Kaskhedikar S.G.,
  2D-QSAR Analysis of Oxadiazole Substituted
  α-Isopropoxy Phenylpropionic Acids as
  PPAR-α & PPAR-γ Agonists, *E-J. Chem.*,
  2004, 01(03), 170-177.
- 9 Soni L.K., Hanumantharao P., Sambasivarao S.V., Gupta A. K, Arockia Babu M., and Kaskhedikar S.G., 3D-QSAR Analysis of Oxadiazole Substituted α-Isopropoxy Phenylpropionic Acids as PPAR-α & PPAR-γ Agonists, *Indian Drugs*, 2003, 40 (11), 627-635.
- Hemlatha R., Soni L.K., Gupta A.K. and Kaskhedikar S.G., QSAR Analysis of 5-Aryl Thiazolidine-2, 4-diones as PPAR-α and

PPAR-γ Agonists, *Indian J. Chem. Section B*, (Accepted).

- 11 Acton J.J., Black R.M., Jones A.B., Moller D.E., Colwell L., Doebber T.W., MacNaul K.L., Berger J. and Wooda H.B., Bioorg. Med. Chem. Letts., 2005, 15, 357–362.
- 12 CS Chemoffice 2001 Software Package, Version 6.0 Supplied by Cambridge Soft Corporation, Software Publishers Association, 1730 M Street, suite 700, Washington D. C. 20036(202) 452-1600, U.S.A
- 13 Kier L B (1971) Molecular Orbital Theory in Drug Research, pp. 37-67, Academic Press New York
- 14 Gupta A.K, Arockia B.M and Kaskhedikar S.G., Indian. J. Pharm. Sci., 2004,66, 396-402.

\*\*\*\*\*